Chemoprevention of prostate cancer by D,L-sulforaphane is augmented by pharmacological inhibition of autophagy

Cancer Research

Volumn 73, Issue 19, 2013, Pages 5985-5995

  Vyas, Avani R ^a   Hahm, Eun Ryeong ^a   Arlotti, Julie A ^b   Watkins, Simon ^a   Stolz, Donna Beer ^a   Desai, Dhimant ^c   Amin, Shantu ^c   Singh, Shivendra V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOPHAGY PROTEIN 5; CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN; SULFORAPHANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; POORLY DIFFERENTIATED PROSTATE CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; TRANSMISSION ELECTRON MICROSCOPY; WELL DIFFERENTIATED PROSTATE CANCER;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIMALARIALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; BLOOD PROTEINS; BLOTTING, WESTERN; CELL PROLIFERATION; CHLOROQUINE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; ISOTHIOCYANATES; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84885035608     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0755     Document Type: Article

References (50)

1. Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr 2004;134:1134-8.
2. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000;9:795-804.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
4. Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 2001;56:5-51.
5. Singh SV, Singh K. Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. Carcinogenesis 2012;33:1833-42.
6. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A 1994;91:3147-50.
7. Conaway CC, Wang CX, Pittman B, Yang YM, Schwartz JE, Tian D, et al. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res 2005;65:8548-57.
8. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, et al. Sulforaphane inhibits extracellular, intracellular, and antibioticresistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002;99:7610-5.
9. Chung FL, Conaway CC, Rao CV, Reddy BS. Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis 2000;21:2287-91.
10. Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 2009;69:2117-25.
11. Keum YS, Khor TO, Lin W, Shen G, Kwon KH, Barve A, et al. Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res 2009;26:2324-31.
12. Singh AV, Xiao D, Lew KL, Dhir R, Singh SV. Sulforaphane induces caspase-mediated apoptosis in cultured PC-3 human prostate cancer cells and retards growth of PC-3 xenografts in vivo. Carcinogenesis 2004;25:83-90.
13. Singh SV, Herman-Antosiewicz A, Singh AV, Lew KL, Srivastava SK, Kamath R, et al. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem 2004;279:25813-22.
14. Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem 2005;280:19911-24.
15. Choi S, Singh SV. Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer chemopreventive agent. Cancer Res 2005;65:2035-43.
16. Bertl E, Bartsch H, Gerhäuser C. Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther 2006;5:575-85.
17. Myzak MC, Karplus PA, Chung FL, Dashwood RH. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 2004;64:5767-74.
18. Xu C, Shen G, Chen C, Gèlinas C, Kong AN. Suppression of NF-kB and NF-kB-regulated gene expression by sulforaphane and PEITCthrough IkBa, IKK pathway in human prostate cancer PC-3 cells. Oncogene 2005;24:4486-95.
19. Hahm ER, Singh SV. Sulforaphane inhibits constitutive and interleukin-6-induced activation of signal transducer and activator of transcription 3 in prostate cancer cells. Cancer Prev Res 2010;3:484-94.
20. Kim SH, Singh SV. D, L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther 2009;8:1946-54.
21. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
22. Herman-Antosiewicz A, Johnson DE, Singh SV. Sulforaphane causes autophagy to inhibit release of cytochrome c and apoptosis in human prostate cancer cells. Cancer Res 2006;66:5828-35.
23. Dikic I, Johansen T, Kirkin V. Selective autophagy in cancer development and therapy. Cancer Res 2010;70:3431-4.
24. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005;5:726-34.
25. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
26. Powolny AA, Bommareddy A, Hahm ER, Normolle DP, Beumer JH, Nelson JB, et al. Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst 2011;103:571-84.
27. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
28. Michihara A, Toda K, Kubo T, Fujiwara Y, Akasaki K, Tsuji H. Disruptive effect of chloroquine on lysosomes in cultured rat hepatocytes. Biol Pharm Bull 2005;28:947-51.
29. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008;172:236-46.
30. Hu YL, Jahangiri A, DeLay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res 2012;72:4294-9.
31. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Mycinduced model of lymphoma. J Clin Invest 2007;117:326-36.
32. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-8.
33. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
34. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-83.
35. Pyo JO, Nah J, Jung YK. Molecules and their functions in autophagy. Exp Mol Med 2012;44:73-80.
36. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000;5 Suppl 1: 3-10.
37. Xiao D, Powolny AA, Antosiewicz J, Hahm ER, Bommareddy A, Zeng Y, et al. Cellular responses to cancer chemopreventive agent D, L-sulforaphane in human prostate cancer cells are initiated by mitochondrial reactive oxygen species. Pharm Res 2009;26:1729-38.
38. Nishikawa T, Tsuno NH, Okaji Y, Shuno Y, Sasaki K, Hongo K, et al. Inhibition of autophagy potentiates sulforaphane-induced apoptosis in human colon cancer cells. Ann Surg Oncol 2010;17:592-602.
39. Jeong HS, Choi HY, Lee ER, Kim JH, Jeon K, Lee HJ, et al. Involvement of caspase-9 in autophagy-mediated cell survival pathway. Biochim Biophys Acta 2011;1813:80-90.
40. Kanematsu S, Uehara N, Miki H, Yoshizawa K, Kawanaka A, Yuri T, et al. Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res 2010;30:3381-90.
41. Naumann P, Fortunato F, Zentgraf H, Büchler MW, Herr I, Werner J. Autophagy and cell death signaling following dietary sulforaphane act independently of each other and require oxidative stress in pancreatic cancer. Int J Oncol 2011;39:101-9.
42. Singh SV, Powolny AA, Stan SD, Xiao D, Arlotti JA, Warin R, et al. Garlic constituent diallyl trisulfide prevents development of poorly differentiated prostate cancer and pulmonary metastasis multiplicity in TRAMP mice. Cancer Res 2008;68:9503-11.
43. Kanoh Y, Ohtani H, Egawa S, Baba S, Akahoshi T. Levels of acute inflammatory biomarkers in advanced prostate cancer patients with a2-macroglobulin deficiency. Int J Oncol 2011;39:1553-8.
44. Jayapalan JJ, Ng KL, Razack AH, Hashim OH. Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses. Electrophoresis 2012;33:1855-62.
45. Rizzi F, Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 2010;17:R1-17.
46. Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, et al. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression. Carcinogenesis 2004;25:2217-24.
47. Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, et al. Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. Oncogene 2009;28:4344-52.
48. Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Gleave M, et al. Expression of clusterin in prostate cancer correlateswith Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 2006;68:609-14.
49. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
50. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.